Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Bencyclane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.52 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.42 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | AQP3 | Q92482 | 1/20 | 0.38 |
| ▸ | AQP1 | P29972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bencyclane SCHEMBL1568812 | 1.00 | HRH1 (0.52) | HRH1CTSKCTSLCTSBCHRM2 | |
| Bencyclane SCHEMBL20505617 | 0.99 | HRH1 (0.51) | HRH1CTSKCTSLCTSBCHRM2 | |
| Bencyclane SCHEMBL64881 | 0.90 | AQP3 (0.44) | HRH1CTSKCTSLCTSBCHRM2 | |
| Bencyclane SCHEMBL11215911 | 0.83 | HRH1 (0.38) | HRH1CTSKCTSLCTSBALDH1A1 | |
| Pyritinol SCHEMBL10629435 | 0.80 | HRH1 (0.40) | HRH1CTSKCTSLCTSBALDH1A1 | |
| SCHEMBL11666639 | 0.78 | AQP1 (0.43) | HRH1CTSKCTSLCTSBCHRM2 | |
| SCHEMBL13681480 | 0.77 | AQP3 (0.50) | HRH1CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL11444307 | 0.76 | HRH3 (0.50) | CHRM2CHRM1ALDH1A1KDM4EAQP3 | |
| Etafenone SCHEMBL4715940 | 0.75 | ABCB1 (0.48) | ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL14409639 | 0.75 | AQP3 (0.48) | HRH1CHRM2CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1053 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2004075832-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN USING DHEA AND DERIVATIVES THEREOF | LUCAS JOHN M (US) | 2004-09-10 | — | — | WO | claimed |
| CN-1468111-A | Pharmaceutical composition for the treatment of acute, chronic pain and/or neuropathic pain and migraine | �Ʒ� | 2004-01-14 | — | — | CN | claimed |
| US-20030133951-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| US-20020068718-A1 | Chondroprotective/restorative compositions and methods of use thereof | PIERCE SCOTT W (US) | 2002-06-06 | — | — | US | claimed |
| US-20010036943-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-4555398-A | THERMOSETTING OR THERMOPLASTIC RESIN MOLD | CHISSO CORPORATION (JP) | 1985-11-26 | — | — | US | claimed |
| EP-0018773-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING BENCYCLANE FUMARATE, A PROCESS FOR ITS PREPARATION AND AN INCLUSION COMPOUND CONTAINING BENCYCLANE FUMARATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-22 | — | — | EP | claimed |
| US-4352793-A | ANTICONVULSANTS, VASODILATORS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-10-05 | — | — | US | claimed |
| EP-0018773-A1 | A pharmaceutical composition containing bencyclane fumarate, a process for its preparation and an inclusion compound containing bencyclane fumarate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-11-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | HRH1 1733/4885CHRM2 2228/4885CHRM3 2031/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | HRH1 1675/4885CHRM2 557/4885CHRM3 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.